IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10112955 B1

PDFFull Text
Date of Patent:
Oct. 30, 2018

Filed:

Oct. 28, 2016

Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2

Applicant:

Effector Therapeutics, Inc., San Diego, CA (US);

Inventors:

Paul A. Sprengeler, Escondido, CA (US);

Siegfried H. Reich, La Jolla, CA (US);

Justin T. Ernst, San Diego, CA (US);

Stephen E. Webber, San Diego, CA (US);

Mike Shaghafi, San Diego, CA (US);

Douglas Murphy, Escondido, CA (US);

Chinh Tran, San Diego, CA (US);

Assignee:

eFFECTOR Therapeutics, Inc., San Diego, CA (US);

Attorney:

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Primary Examiner:

Paul V Ward

Int. Cl.
CPC ...
C07D 498/04 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 403/14 (2006.01); C07D 239/42 (2006.01); C07D 239/49 (2006.01); C07D 409/12 (2006.01); C07D 417/12 (2006.01); C07D 487/04 (2006.01); C07D 239/48 (2006.01); C07D 409/14 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 473/34 (2006.01); C07D 491/107 (2006.01);
U.S. Cl.
CPC ...
C07D 498/04 (2013.01); C07D 239/42 (2013.01); C07D 239/48 (2013.01); C07D 239/49 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07D 473/34 (2013.01); C07D 487/04 (2013.01); C07D 491/107 (2013.01);
Abstract

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A, A, A, A, A, W, Y, R, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rand subscript 'n' are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Find Patent Forward Citations

Loading…